Spots Global Cancer Trial Database for Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
Official Title: Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma
Study ID: NCT01296659
Conditions
Interventions
Study Description
Brief Summary: Ridaforolimus has been tested in almost 2 dozen studies; however, it has not previously been tested in combination with the standard of care chemotherapy for sarcoma as this study will. We will be looking to see if Ridaforolimus given with SOC chemo (AIM or TG) is well tolerated and to determine a Phase 2 dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
Contact Details
Name: Monica Mita, MD
Affiliation: The University of Texas Health Science Center at San Antonio
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
